Vera Therapeutics Analyst Price Targets - Benzinga

Vera Therapeutics Inc

VERANASDAQ

Trade with Public

Trade with Public

$33.78

-1.50-4.25%

At close: Sep 8, 5:00 PM EST

$34.10

-1.18-3.34%

Pre-Market: 7:15 AM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Vera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vera Therapeutics (VERA).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

1S.Buy

12Buy

1Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$68Upside to Avg. PT+98.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 8, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$76→$83
Aug 17, 2026	Wedbush	Laura Chico	Maintained	Neutral	$34
Aug 12, 2026	HC Wainwright & Co.	Arthur He	PT Cut	Buy	$125→$90
Aug 11, 2026	Wedbush	Laura Chico	PT Cut	Neutral	$43→$34
Jul 8, 2026	TD Cowen	Ritu Baral	PT Raise	Buy	$73→$78
Jul 8, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$56→$76
Jul 8, 2026	Wedbush	Laura Chico	PT Raise	Neutral	$35→$43
Jul 8, 2026	HC Wainwright & Co.	Arthur He	PT Raise	Buy	$110→$125
Jul 7, 2026	B of A Securities	Dina Ramadane	PT Raise	Buy	$65→$70
May 15, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$95→$91
Mar 11, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	$88
Mar 2, 2026	HC Wainwright & Co.	Arthur He	PT Raise	Buy	$90→$110
Dec 19, 2025	B of A Securities	Dina Ramadane	PT Raise	Buy	$48→$66
Dec 19, 2025	Goldman Sachs	Paul Choi	PT Raise	Buy	$55→$95
Dec 19, 2025	JP Morgan	Anupam Rama	PT Cut	Overweight	$99→$96
Dec 11, 2025	Wedbush	Laura Chico	PT Raise	Neutral	$23→$33
Dec 8, 2025	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$75→$97
Dec 5, 2025	TD Cowen	Ritu Baral	PT Raise	Buy	$60→$73
Dec 3, 2025	JP Morgan	Anupam Rama	PT Raise	Overweight	$52→$99
Nov 10, 2025	HC Wainwright & Co.	Arthur He	PT Raise	Buy	$85→$90

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $76 to $83.

Benzinga Newsdesk

PRO
Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target

Wedbush analyst Laura Chico reiterates Vera Therapeutics (NASDAQ:VERA) with a Neutral and maintains $34 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $125 to $90.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $43 to $34.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78

TD Cowen analyst Ritu Baral maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $73 to $78.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $76

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $56 to $76.

Benzinga Newsdesk